Literature DB >> 3460752

Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.

H Tapiero, J N Munck, A Fourcade.   

Abstract

The relationship between accumulation, retention and cytotoxicity of various anthracyclines was investigated in Friend leukaemia cells growing in vitro. By comparison to that of adriamycin (ADM) and epi-adriamycin (Epi-ADM), the uptake of demethoxy-daunorubicin (DM-DNR) and THP-adriamycin (THP-ADM) is a rapid process. In cells exposed to DM-DNR or THP-ADM, a 50% accumulation is reached in less than 2 min, whereas 80 min and up to 4 hours are needed for epi-ADM or ADM, respectively. More than 95% of these anthracyclines are accumulated and retained in the nuclear fraction. Following a short cell exposure, the intracellular concentrations of the rapidly incorporated drugs (DM-DNR or THP-ADM) decrease with the cell density. After cell exposure to one of these drugs followed by growth in drug-free medium, the cytotoxic activity is related to the ease with which the anthracycline accumulates in cells. Since the pharmacological properties of these anthracyclines differ, and because cytotoxic activity correlates with these properties, plasma and intracellular concentrations of ADM and THP-ADM were studied after intravenous administration in leukaemic and non-leukaemic patients with various white blood cell concentrations. Since the pharmacokinetic studies in vivo correlated to in vitro parameters, it is concluded that administration modalities have to be determined, adapted to each patient, and considered differently according to the anthracycline used.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3460752

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  4 in total

1.  Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.

Authors:  Patrick Favoulet; Laurent Benoit; Liliana Osmak; Emmanuel Polycarpe; Philippe Esquis; Christian Duvillard; Boris Guiu; Patrick Rat; Jean Pierre Favre; Bruno Chauffert
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

2.  4'-O-tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study.

Authors:  H Samonigg; A K Kasparek; H Stöger; M Schmid; B Eber; G Stark; V Weinrauch; K Pfeiffer; M Smola; P Steindorfer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.

Authors:  R M Mader; H Zilg; O Schlappack; G G Steger; M Baur; B Greifenberg; U Heberle; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  In vitro interaction of lithotripter shock waves and cytotoxic drugs.

Authors:  S Gambihler; M Delius
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.